Condition: Acute Myeloid Leukemia · Myelodysplastic Syndrome · Sponsor: Celyad Oncology SA
An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patient. A maximum of 27 r/r AML/MDS patients will be evaluated in this study in case of no dose limiting toxicity (DLT) and no replacement of patients.
This description comes directly from the study's public registry record.
Frederic LEHMANN, MD, PhD · 003210394100 · flehmann@celyad.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Cancer Center | Jacksonville, Florida, United States | Not Yet Recruiting |
| University of Kansas Cancer Center | Fairway, Kansas, United States | Recruiting |
| Uz Leuven | Leuven, Belgium | Recruiting |
| Chu Liege | Liège, Belgium | Recruiting |
| AZ DELTA | Roeselare, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04167696